<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312830</url>
  </required_header>
  <id_info>
    <org_study_id>S57284</org_study_id>
    <nct_id>NCT02312830</nct_id>
  </id_info>
  <brief_title>Belgian Cross-sectional Allogeneic Transplant Survivor Study</brief_title>
  <acronym>BE-C@TS</acronym>
  <official_title>Belgian Cross-sectional Allogeneic Transplant Survivor Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the increasing successful use of allogeneic hematopoietic stem cell transplantation&#xD;
      (HSCT) to cure advanced hematological disease, it becomes essential to evaluate the long-term&#xD;
      effects of such a drastic treatment.&#xD;
&#xD;
      This study investigates the prevalence of several demographic, psychosocial and behavioral&#xD;
      aspects of survivorship after an allogeneic transplantation. Income, return to work, social&#xD;
      isolation, pain, medication adherence, influenza vaccination status, alcohol use, smoking&#xD;
      habits, drug use, healthy diet, prevention of UV exposure, physical activity, functional&#xD;
      status/Quality of life (QoL), couple life/sexual function, depression, anxiety, spirituality&#xD;
      and resilience will be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross sectional study, where participants are interviewed and fill in a self&#xD;
      reported survey. The interview and survey are only taken once. It is non interventional&#xD;
      because the patients only give us extra information, which is not usually recorded in our&#xD;
      medical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>composite outcome: prevalence of several demographic, psychosocial and behavioral aspects of survivorship after an allogeneic transplantation</measure>
    <time_frame>The interview/survey will happen once per patient and will be offered to all transplant survivors (minimum 2 years post transplant) coming to the clinic between Nov 2014-Nov 2016. No follow up included.</time_frame>
    <description>This is a cross sectional study, assessing several aspects of survivorship with multiple validated questionnaires (EQ5D, PHQ9, GAD, SFQ, etc). These questionnaires are only taken once in all survivors approached for the study.</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Hematopoietic Stem Cell Transplantation, Allogeneic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients transplanted in UZ Leuven between 1992 and 2012 with an allogeneic donor&#xD;
        (i.e. being at least 2 years post-Tx) - Hematopoietic Stem Cell Transplantation, presenting&#xD;
        for a standard medical check up&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to read and write in Dutch&#xD;
&#xD;
          -  Age above 18 years at time of transplant&#xD;
&#xD;
          -  Transplanted in UZ Leuven between 1992 and 2012 with an allogeneic donor (i.e. being&#xD;
             at least 2 years post-Tx)&#xD;
&#xD;
          -  Presenting for a periodic health check in UZLEUVEN from November 15th, 2014 to&#xD;
             November 15th 2016&#xD;
&#xD;
          -  Willing to provide oral and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to communicate fluently in Dutch&#xD;
&#xD;
          -  Presenting with major visual, hearing, cognitive or psychiatric conditions precluding&#xD;
             participation&#xD;
&#xD;
          -  Presenting with relapse or other major illness, with less than 6 months expected&#xD;
             survival&#xD;
&#xD;
          -  Hospitalized for a life-threatening condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

